187 related articles for article (PubMed ID: 34702313)
1. The role of PDGFRA as a therapeutic target in young colorectal cancer patients.
Kim TW; Hong HK; Lee C; Kim S; Lee WY; Yun SH; Kim HC; Huh JW; Park YA; Joung JG; Park WY; Cho YB
J Transl Med; 2021 Oct; 19(1):446. PubMed ID: 34702313
[TBL] [Abstract][Full Text] [Related]
2. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
[TBL] [Abstract][Full Text] [Related]
4. Consensus molecular subtype classification of colorectal adenomas.
Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
[TBL] [Abstract][Full Text] [Related]
5. Genomic landscape and expression profile of consensus molecular subtype four of colorectal cancer.
Lu Y; Gu D; Zhao C; Sun Y; Li W; He L; Wang X; Kou Z; Su J; Guo F
Front Immunol; 2023; 14():1160052. PubMed ID: 37404825
[TBL] [Abstract][Full Text] [Related]
6. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
Chen RM; Chiou YS; Chong QY; Poh HM; Tan TZ; Zhang MY; Ma L; Zhu T; Pandey V; Basappa ; Kumar AP; Lobie PE
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835445
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
[TBL] [Abstract][Full Text] [Related]
9. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
[TBL] [Abstract][Full Text] [Related]
12. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.
Sveen A; Bruun J; Eide PW; Eilertsen IA; Ramirez L; Murumägi A; Arjama M; Danielsen SA; Kryeziu K; Elez E; Tabernero J; Guinney J; Palmer HG; Nesbakken A; Kallioniemi O; Dienstmann R; Lothe RA
Clin Cancer Res; 2018 Feb; 24(4):794-806. PubMed ID: 29242316
[No Abstract] [Full Text] [Related]
14. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
[TBL] [Abstract][Full Text] [Related]
15. The clinical and immune features of CD14 in colorectal cancer identified via large-scale analysis.
Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106966. PubMed ID: 33182067
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2.
Fan C; Lin Y; Mao Y; Huang Z; Liu AY; Ma H; Yu D; Maitikabili A; Xiao H; Zhang C; Liu F; Luo Q; Ouyang G
Oncotarget; 2016 Apr; 7(16):21825-39. PubMed ID: 26968810
[TBL] [Abstract][Full Text] [Related]
17. Expression of SATB1 promotes the growth and metastasis of colorectal cancer.
Zhang Y; Tian X; Ji H; Guan X; Xu W; Dong B; Zhao M; Wei M; Ye C; Sun Y; Yuan X; Yang C; Hao C
PLoS One; 2014; 9(6):e100413. PubMed ID: 24971456
[TBL] [Abstract][Full Text] [Related]
18. A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.
Ubink I; Elias SG; Moelans CB; Laclé MM; van Grevenstein WMU; van Diest PJ; Borel Rinkes IHM; Kranenburg O
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376187
[TBL] [Abstract][Full Text] [Related]
19. Protein tyrosine phosphatase 1B targets PITX1/p120RasGAP thus showing therapeutic potential in colorectal carcinoma.
Teng HW; Hung MH; Chen LJ; Chang MJ; Hsieh FS; Tsai MH; Huang JW; Lin CL; Tseng HW; Kuo ZK; Jiang JK; Yang SH; Shiau CW; Chen KF
Sci Rep; 2016 Oct; 6():35308. PubMed ID: 27752061
[TBL] [Abstract][Full Text] [Related]
20. Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype.
Cherradi S; Martineau P; Gongora C; Del Rio M
Cancer Manag Res; 2019; 11():1337-1348. PubMed ID: 30863148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
